Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
balapiravir
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Balapiravir is an orally administered experimental antiviral drug developed as a prodrug of the nucleoside analogue 4′-azidocytidine (R1479). It was originally designed for the treatment of chronic hepatitis C virus (HCV) infection and later investigated for dengue fever. Balapiravir acts as a polymerase inhibitor, specifically targeting viral RNA-dependent RNA polymerases such as HCV NS5B, thereby inhibiting viral replication. The drug demonstrated dose-dependent reductions in HCV viral load in early clinical studies but was discontinued due to safety concerns, including lymphopenia at higher doses and lack of efficacy in dengue trials. Balapiravir is classified as a small molecule antiviral[1][2][3][4][5][7].
- Other names
- 4'-C-Azidocytidine 2',3',5'-tris(2-methylpropanoate)balapiravir
02
Targets
RdRp (Coronavirus RNA-dependent RNA polymerase)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on balapiravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on balapiravir.